Abstract | BACKGROUND: METHODS: RESULTS: In the study of patients with deep venous thrombosis, the incidence of recurrence at day 92 was 2.9% in the idraparinux group as compared with 3.0% in the standard-therapy group (odds ratio, 0.98; 95% confidence interval [CI], 0.63 to 1.50), a result that satisfied the prespecified noninferiority requirement. At 6 months, the hazard ratio for idraparinux was 1.01. The rates of clinically relevant bleeding at day 92 were 4.5% in the idraparinux group and 7.0% in the standard-therapy group (P=0.004). At 6 months, bleeding rates were similar. In the study of patients with pulmonary embolism, the incidence of recurrence at day 92 was 3.4% in the idraparinux group and 1.6% in the standard-therapy group (odds ratio, 2.14; 95% CI, 1.21 to 3.78), a finding that did not meet the noninferiority requirement. CONCLUSIONS:
|
Authors | van Gogh Investigators, Harry R Buller, Ander T Cohen, Bruce Davidson, Hervé Decousus, Alex S Gallus, Michael Gent, Gerard Pillion, Franco Piovella, Martin H Prins, Gary E Raskob |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 357
Issue 11
Pg. 1094-104
(Sep 13 2007)
ISSN: 1533-4406 [Electronic] United States |
PMID | 17855670
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2007 Massachusetts Medical Society. |
Chemical References |
- Anticoagulants
- Oligosaccharides
- Vitamin K
- idraparinux
- Heparin
|
Topics |
- Anticoagulants
(adverse effects, therapeutic use)
- Female
- Follow-Up Studies
- Hemorrhage
(chemically induced)
- Heparin
(adverse effects, therapeutic use)
- Humans
- Incidence
- Male
- Middle Aged
- Oligosaccharides
(adverse effects, therapeutic use)
- Pulmonary Embolism
(drug therapy, mortality)
- Recurrence
- Treatment Outcome
- Venous Thrombosis
(drug therapy, mortality)
- Vitamin K
(antagonists & inhibitors)
|